To bridge the gap between the homozygous SNP alleles (–617A/A) in the NRF2 gene and the high overall survival of lung cancer patients shown in this study, we need to carry out further clinical follow-up studies with lung cancer patients (p-stages III and IV) who have been subjected to chemotherapeutic treatments. Here, NFE2L2 is linked to lung carcinoma.